Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of isolated nucleic acid and its application

A technology of nucleic acid and carrier, applied in isolated nucleic acid and its application field, can solve the problem that there is no preventive vaccine and therapeutic drug for Zika virus, and achieve good stability

Active Publication Date: 2021-07-13
BRAVOVAX +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no commercial Zika virus preventive vaccines and therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of isolated nucleic acid and its application
  • A kind of isolated nucleic acid and its application
  • A kind of isolated nucleic acid and its application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0069] The method for preparing Env protein provided by the embodiment of the present invention comprises culturing the above-mentioned recombinant cells or recombinant bacteria. Specifically, the method includes culturing the above-mentioned recombinant cells or bacteria, and then isolating and purifying the Env protein from the culture, which is the Zika virus antigenic protein.

[0070] The Zika virus vaccine provided by the embodiment of the present invention includes the above-mentioned nucleic acid, the above-mentioned vector, the above-mentioned recombinant adenovirus or the Env protein prepared by the above-mentioned method for preparing Env protein.

no. 1 example

[0073] The pAd5-CMV-M-Env-PolyA plasmid was prepared.

[0074] 1. Construction of transfer plasmid (pDONR221-M-Env-PolyA)

[0075] 1.1. Gene synthesis and primer design

[0076] According to the sequence shown in SEQ ID NO.3, let Gene Synthesis Company synthesize the M-Env sequence.

[0077] Using the M-Env sequence (sequence shown in SEQ ID NO.3) as a template, upstream and downstream primers (primers were synthesized by Invitrogen) were designed for PCR amplification.

[0078] Wherein, the sequence of the upstream primer (M-Env-F) is as follows: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGCTGTGACGCTCCCCTCCCATTC-3' (as shown in SEQ ID NO.8);

[0079] The sequence of the downstream primer (SV40-R) is as follows: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCAGATGATAAGATACATTGATGAGT-3' (as shown in SEQ ID NO.9).

[0080] 1.2. PCR amplification

[0081] Amplification system: 2 μL of upstream and downstream primers, 1 μL of gene synthesis plasmid template, 25 μL of Primer STAR mi...

no. 2 example

[0092] Preparation of linearized viral vector rAd5-M-Env-PolyA.

[0093] 3. Amplification of Adenoviral Vectors

[0094] 3.1. The pAd5-CMV-M-Env-PolyA plasmid sequenced correctly in step 2.3 was transformed into Escherichia coli TOP10 competent cells, and spread on a solid LB plate containing Amp antibiotics. Negative control for comparison: Transform Escherichia coli ccdBsuvival competent cells (purchased from Invitrogen, USA) with pAd5-CMV / V5-Dest plasmid (purchased from Invitrogen, USA), and spread on solid LB plates containing Amp antibiotics.

[0095] 3.2. The next day, pick out the single clones on the LB plate respectively, and inoculate them in the liquid medium containing 200mL Amp. pAd-CMV / V5-Dest plasmid.

[0096] 4. Adenoviral vector linearization treatment The pAd5-CMV-M-Env-PolyA plasmid and pAd-CMV / V5-Dest plasmid obtained in step 3.2 were respectively treated with PacI restriction endonuclease (purchased from NEB, USA), 37 Digest for 3 hours at ℃, and the di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an isolated nucleic acid and its application, and relates to the technical field of biomolecules. The base sequence of the nucleic acid is as shown in any one of (1) to (3): (1) the base sequence is as shown in SEQ ID NO.3; (2) the 1st to 225th base sequence is as shown in SEQ ID NO As shown in .1, the 226th to 1737th base sequence encodes Env protein, and the amino acid sequence of Env protein is shown in SEQ ID NO.4; (3) the 1st to 225th base sequence encodes M protein, and the 226th to 1737th base sequence The base sequence is shown in SEQ ID NO.2, and the amino acid sequence of the M protein is shown in SEQ ID NO.5. The nucleic acid can express Zika virus immune antigens in large quantities, and is beneficial to the research of Zika virus vaccines or Zika virus therapeutic drugs.

Description

technical field [0001] The invention relates to the technical field of biomolecules, in particular to an isolated nucleic acid and its application. Background technique [0002] Zika virus (Zika virus) was first discovered in 1947 in the Zika Forest of Uganda, Africa. It is parasitic in rhesus monkeys and is mainly transmitted through mosquito bites. At present, about 80% of Zika virus-infected individuals do not show obvious clinical symptoms, and a small number of infected individuals with clinical symptoms show fever, rash, arthralgia, muscle pain, headache, vomiting and conjunctivitis. It usually lasts for more than 1 week and is relatively mild. [0003] Zika virus vectors are Aedes aegypti and Aedes albopictus, which are active year-round in many parts of the world, including most of the southern coastal states of the United States and many resort areas in Latin America and the Pacific Ocean. Apart from early prevention, there is no effective treatment for Zika virus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/40C07K14/18C12N15/861C12N7/01A61K39/12A61P31/14
CPCA61K39/12A61K2039/5256A61K2039/53A61P31/14C07K14/005C12N7/00C12N15/86C12N2710/10043C12N2770/24122C12N2770/24134Y02A50/30
Inventor 谌章舟慕婷赵萍董威
Owner BRAVOVAX
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com